Novotech Opens Tokyo Office to Expand Japan Clinical Trial Operations
- Novotech, a global biotech CRO, opened a new Tokyo office to strengthen its Japan presence and support Japanese biopharma companies advancing clinical programs.
- The office serves as a strategic operations hub connecting sponsors across Asia-Pacific, the U.S., and Europe, leveraging Novotech's expertise in oncology, rare diseases, CNS, infectious diseases, immunology, and advanced therapies.
Operational Impact
Novotech's Tokyo hub reduces regional fragmentation for sponsors running cross-border trials, enabling Japanese biotech clients to access integrated clinical services across APAC, U.S., and European markets without managing multiple regional vendors.
Source: Contract Pharma Breaking News RSS
Novotech Opens Tokyo Office to Expand Clinical Services for Japanese Biotech Sponsors
- Novotech inaugurated a Tokyo hub at Shinjuku i-Land Tower under Country Head Takeshi Mori, deepening clinical trial operations in Japan and strengthening support for Japanese biopharma sponsors entering global markets.
- The office integrates Novotech's Asia-Pacific network (30+ offices, 7,000+ trial sites) with early-phase development in Australia, FDA-aligned protocol support, and U.S. scientific expertise to enable cross-border trial management without multiple regional vendors.
- The expansion positions Novotech to serve Japan's growing biotech sector as emerging and mid-size companies seek to advance programs toward FDA, EMA, and PMDA regulatory submissions.
Operational Impact
Japanese biopharma sponsors can now access Novotech's integrated clinical development platform—including early-phase capabilities in Australia and FDA-aligned protocol support—through a dedicated Tokyo hub, reducing the need to engage multiple regional CRO partners for cross-border trials.
Source: PharmaSource RSS
Emmes Group Appoints Rama Kondru as CEO; Prioritizes AI and Clinical Technology Integration
- Dr. Rama Kondru, former Co-CEO of Medidata Solutions, assumes CEO role at Emmes Group, bringing 25 years of pharma, healthcare tech, and data science experience.
- Kondru led Veridix, Emmes' AI and data sciences subsidiary, and plans to combine AI, technology, and clinical expertise to accelerate trial design and execution.
Operational Impact
Emmes' appointment of a technology-platform scaling executive as CEO may accelerate adoption of AI and cloud-based trial infrastructure across the CRO's customer base, potentially reshaping competitive positioning in digital clinical development.
Source: Contract Pharma Breaking News RSS
References
- Contract Pharma Breaking News RSS — Novotech Opens Tokyo Office to Expand Japan Clinical Trial Operations
- PharmaSource RSS — Novotech Opens Tokyo Office to Expand Clinical Services for Japanese Biotech Sponsors
- Contract Pharma Breaking News RSS — Emmes Group Appoints Rama Kondru as CEO; Prioritizes AI and Clinical Technology Inte